Breast implants market is estimated to be valued at USD 1.54 Bn in 2024 and is expected to exhibit a CAGR of 4.7% over the forecast period (2024-2031). The global breast implants market is witnessing significant growth owing to factors such as rising prevalence of breast cancer, growing awareness about breast aesthetics procedure, and increasing healthcare expenditure. Furthermore, the favorable reimbursement policies for breast implant procedures in developed regions are supplementing the market growth.
Market Dynamics:
Rising prevalence of breast cancer and reconstruction procedures after mastectomy has been a key growth driver for the global breast implants market. According to World Health Organization, breast cancer is the most common cancer in women worldwide with over 2 million new cases registered in 2020. The growing adoption of breast reconstruction post mastectomy aids in enhancing the self-esteem and quality of life. This has increased the demand for breast implants. Additionally, growing awareness about breast aesthetics procedures through social media campaigns has boosted the demand for breast augmentation globally. The normalization of breast aesthetics as a social trend continues to attract more women to opt for breast implants for cosmetic enhancement. Moreover, the availability of reimbursement policies for breast reconstruction surgeries especially in developed regions is fueling the market growth.
Increasing Demand for Aesthetics is Driving the Market Growth
The global breast implants market has been witnessing significant growth over the past few years owing to the rising demand for cosmetic surgeries and breast augmentation procedures. With increasing focus on physical appearance and aesthetics, more and more women, especially in developed nations, are opting for breast implants to enhance their confidence and looks. According to the American Society of Plastic Surgeons, breast augmentation surgery is the most popular cosmetic procedure performed in the U.S. This growing demand for aesthetic enhancement has prompted manufacturers to roll out innovative breast implant solutions tailored to meet patients' expectations. Advancements in breast implant technology, such as the development of highly cohesive silicone gel-filled implants, have also fueled the market expansion.
Strong Advertising and Marketing Strategies are Boosting Market Revenues
Aggressive promotional activities and effective marketing campaigns by breast implant manufacturers have played a crucial role in raising awareness and promoting their products. Companies extensively market their implants through various online and offline channels to reach a wider consumer base. Informative websites, brochures, medical journals, and social media platforms highlight the benefits of undergoing breast augmentation while positioning such procedures as safe and routine. Celebrity endorsement further helps normalize the concept of cosmetic enhancement and contributes to the positive brand image of breast implant brands. This result-driven promotional approach has helped boost the market revenues over the past few years.
Lack of Standardization in Regulation Impedes the Market Growth
Despite rapid market growth, lack of uniform regulatory standards across countries continues to pose a serious challenge for industry players. Regulation and approval processes for breast implants differ significantly in various geographic regions. For instance, while silicone gel-filled implants were re-approved for use in the U.S. in 2006, some countries like Canada still restrict their use citing safety concerns. Such disparate regulatory norms often lead to product recalls and legal issues, negatively impacting company sales and brand reputation. Moreover, inadequate post-market surveillance and limited long-term safety data on newer implants add to regulatory uncertainties. Addressing this issue through global harmonization of regulatory policies could help foster a more conducive growth environment for breast implant manufacturers.
Safety Concerns Related to Implant Ruptures Deter Patients
While modern breast implants continue to evolve in terms of biocompatibility and durability, occasional leakage or rupture still remains a pertinent risk that deters some potential patients. Despite being certified for 10-year usages, there are cases where implants have been reported to rupture even earlier due to factors like trauma or normal daily activities. While gel bleed is usually mild and asymptomatic, rupture may require additional surgery for removal. Associated complications such as capsular contracture due to leaked gel or saline further discourage patients. Industry players need to focus on developing truly rupture-resistant implants through advanced materials and technologies to build consumer confidence over the long run.
Medical Tourism in Developing Nations Presents Commercial Opportunities
Growing medical tourism in Asian countries like Thailand, India, and Mexico has opened up new avenues of growth for breast implant suppliers. Developing nations offer breast augmentation at significantly lower costs compared to developed markets while still maintaining international quality standards. Several board-certified international surgeons in these countries offer attractive medical tourism packages entailing surgery, accommodation, and travel expenses. This cost-effective alternative has been a major draw for patients from Western nations. By partnering with key clinicians, hospitals and tourism boards in popular medical tourism destinations, breast implant companies can leverage the substantial business opportunities emerging from this regional sector.
*Link: https://www.coherentmarketinsights.com/market-insight/breast-implants-market-1309
Key Development
- On March 19, 2024, The Aesthetic Society, the leading authority on aesthetic plastic surgery, and The Aesthetic Foundation, the philanthropic research and education arm of The Aesthetic Society, announced the launch of the American Registry for Breast Implant Surveillance (ARISE), powered by their innovative Aesthetic One app. ARISE revolutionizes the landscape of breast implant registries by partnering with Aesthetic One, an U.S. Food and Drug Administration recognized app dedicated to digital registration of breast implant devices used in aesthetic and reconstructive cases.
- On January 2, 2024, CollPlant Biotechnologies, a regenerative and aesthetics medicine company, announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, and regenerative breast implants. Currently, there are no commercial products that allow the regeneration of soft tissues such as the breast.
- In February 2022, CELLINK, a BICO Group company and CollPlant Biotechnologies, a regenerative and aesthetic medicine company, announced a collaboration agreement. Under the terms of agreement, CELLINK's high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants.
- In May 2021, GC Aesthetics, a medical technology company, announced the launch of its next generation of breast implants, PERLE. PERLE is a highly innovative line of smooth breast implants that features a proprietary surface technology (BioQ).
Key Players: Abbvie, Inc., Ideal Implant Inc, GC Aesthetics, Shanghai Kangning Medical Device Co., Ltd, Polytech Health & Aesthetics GmbH, Mentor Worldwide LLC, Laboratoires Anios, CEREPLAS, Establishment Labs S.A., GROUPE SEBBIN SAS, HansBiomed Co., Ltd, Sientra, Inc., Sebbin, Arion Laboratories, Establishment Labs SA, Silimed, and CollPlant Biotechnologies
